(24) Accordingly, LCNEC could be divided into two major subsets, one with SCLC-like mutations, including the biallelic inactivation of tumor protein RB1 and TP53, and the other with NSCLC-like mutations, including biallelic inactivation of KEAP1/STK11. This evidence concerns the gene STK11 and large cell neuroendocrine carcinoma.